Tadalafil Once a Day for Men with Erectile Dysfunction: Is It Superior than On-Demand Administration?

Authors

  • Dimas Tri Prasetyo Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Putu Angga Risky Raharja Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Ben Julian Mantiri Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • David Ralph Lienhardt Ringoringo Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Irham Arif Rahman Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Jody Felizio Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Made Parulian Tambunan Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Syifa Fauziah Fadhly Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Harrina Erlianti Rahardjo Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Keywords:

Tadalafil, once-a-day, erectile dysfunction, IIEF.

Abstract

Background: Tadalafil is a PDE5I which has been licensed for the treatment of erectile dysfunction (ED) since 2003, is effective from 30 minutes after administration and its efficacy is maintained for up to 36 hours. More recently, it is also given OAD in a lower dose to allow spontaneous sexual activities. However, whether OAD administration is more effective than PRN administration in improving the EF is yet to be established. This study aimed to evaluate whether OAD administration of tadalafil leads to a better improvement of erectile function (EF) in patients with erectile dysfunction (ED) compared to PRN administration. Methods: literature search of electronic database was performed through Medline, Scopus, Cochrane Library, and CINAHL databases. Cochrane Risk of Bias Tool was then employed to assess the risk of bias in each study. Results: initial literature search resulted in 231 hits, but only four studies were included in final selection. Based on our judgements, the study by Kang et al. was the most applicable in our clinical setting. This study showed that subjects who received tadalafil OAD had statistically significant higher increases of mean IIEF-EF (6.5 (SD 4.5) vs 4.9 (SD 4.2), p=0.032), proportion of “yes” responses to SEP-2 (81.8% vs 64.7%, p=0.025), and proportion of “yes” responses to SEP-3 (77.3% vs 60.3%, p=0.034). Conclusion: administration of tadalafil OAD leads to a better improvement of EF compared to PRN administration.

References

Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. EAU guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. 2017.

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinklay JB. Impotence and its medical and physiological correlates: Results of the massacheusetts male aging study. J Urol. 1994;151:54–61.

Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of asian countries. BJU Int. 2005;95(4):609–14.

Suzuki E, Nishimatsu H, Oba S, Takahashi M, Homma Y. Chronic kidney disease and erectile dysfunction. World J Nephrol. 2014;3(4):220–9.

Papadopoulou E, Varouktsi A, Lazaridis A, Boutari C, Doumas M. Erectile dysfunction in chronic kidney disease: From pathophysiology to management. World J Nephrol. 2015;4(3):379–87. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4491929&tool=pmcentrez&rendertype=abstract.

Hatzimouratidis K, Eardley I, Giuliano F, et al. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Eur Urol. 2010;57(5):804–14. Available from: http://uroweb.org/wp-content/uploads/14-Male-Sexual-Dysfunction_LR.pdf.

Curran MP, Keating GM. Tadalafil. Drugs. 2003;63:2203–12.

Buvat J, Büttner H, Hatzimouratidis K, et al. Adherence to initial PDE-5 inhibitor treatment: Randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med. 2013;10(6):1592–602.

Kang DH, Lee JY, Chung JH, et al. Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract. 2012;66(8):813–20.

McMahon C, Kloner RA, Hutter AM, Porst H. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005;2(3):415–27.

Rubio-Aurioles E, Porst H, Kim ED, et al. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012;9(5):1418–29.

Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med. 2009;6(7):2039–48.

Peng Z, Yang L, Dong Q, Wei Q, Liu L, Yang B. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: A systematic review and meta-analyses. Urol Int. 2017;(37):343–52.

Downloads

Published

2019-11-07

How to Cite

Prasetyo, D. T., Raharja, P. A. R., Mantiri, B. J., Ringoringo, D. R. L., Rahman, I. A., Felizio, J., Tambunan, M. P., Fadhly, S. F., & Rahardjo, H. E. (2019). Tadalafil Once a Day for Men with Erectile Dysfunction: Is It Superior than On-Demand Administration?. Acta Medica Indonesiana, 51(3), 275. Retrieved from https://actamedindones.org/index.php/ijim/article/view/746

Issue

Vol. 51 No. 3 (2019): Acta Medica Indonesiana

Section

SPECIAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.